GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study of GS-0272 in Participants With Rheumatoid Arthritis
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 87
- Registration Number
- NCT06031415
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology Associates P.C., Glendale, California, United States
🇰🇷Chungnam National University Hospital, Daejeon, Korea, Republic of
🇺🇸Stanford School of Medicine, Division of Immunology & Rheumatology, Palo Alto, California, United States
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 176
- Registration Number
- NCT06029972
- Locations
- 🇺🇸
Arizona Digestive Health, Sun City, Arizona, United States
🇺🇸GastroSb Weight Loss Clinic, Chula Vista, California, United States
🇺🇸Southern California Research Centers, Coronado, California, United States
Study of Obeldesivir in Children and Adolescents With COVID-19
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 3
- Registration Number
- NCT05996744
- Locations
- 🇺🇸
Trinity Clinical Research, LLC, Centreville, Alabama, United States
🇺🇸Advanced Research Center, Inc., Anaheim, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
- Conditions
- Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 654
- Registration Number
- NCT05840211
- Locations
- 🇺🇸
Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
Study of GS-4528 in Adults With Solid Tumors
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 132
- Registration Number
- NCT05840224
- Locations
- 🇺🇸
The University of Washington/FHCC, Seattle, Washington, United States
🇨🇦The Ottawa Hospital, Ottawa, Canada
🇨🇦University Health Network, Princess Margaret Cancer Centre, Toronto, Canada
Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- Biological: Placebo for GS-6779Biological: Placebo for GS-2829
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 83
- Registration Number
- NCT05770895
- Locations
- 🇳🇿
New Zealand Clinical Research (NZCR), Auckland, New Zealand
🇨🇳Chia-Yi Christian Hospital, Chiayi City, Taiwan
🇨🇳St. Martin De Porres Hospital, Chiayi City, Taiwan
Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 74
- Registration Number
- NCT05765344
- Locations
- 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 41
- Registration Number
- NCT05760300
- Locations
- 🇺🇸
Velocity Clinical Research, New Smyrna Beach, Edgewater, Florida, United States
🇺🇸Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸Floridian Clinical Research, LLC, Miami Lakes, Florida, United States
A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
- Conditions
- HIV Infections
- Interventions
- Drug: Antiretroviral Therapy
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 83
- Registration Number
- NCT05729568
- Locations
- 🇺🇸
Ruane Clinical Research Group, Inc., Los Angeles, California, United States
🇺🇸Mills Clinical Research, Los Angeles, California, United States
🇺🇸UC San Diego (UCSD) AntiViral Research Center (AVRC), San Diego, California, United States
Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 170
- Registration Number
- NCT05718700
- Locations
- 🇦🇹
Medizinische Universität Graz Universitätsklinik für Innere Medizin, Klinische Abteilung für Gastroenterologie und Hepatologie, Graz, Austria
🇦🇹Aö Landeskrankenhaus Hall, Hall in Tirol, Austria
🇦🇹Universitätsklinik für Innere Medizin I Innsbruck, Innsbruck, Austria